The study on more than 350,000 patients taking prescription doses of such medications found the chance of a heart attack or stroke rose by almost 40 per cent.
The study found the increased risk of cardiac side-effects from ibuprofen was similar to those of another arthritis drug, Vioxx, which was withdrawn from the market almost a decade ago when research had suggested it might double the risk of heart attacks, 'The Telegraph' reported.
The research, published in The Lancet, found that for every 1,000 people with a moderate risk of heart disease, around eight would normally have a heart attack or stroke each year.
When similar patients were given one year of treatment with a high dose of ibuprofen (2400mg daily) or diclofenac (150mg daily) that risk rose, with 11 patients suffering the major cardiac events.
The same dosage - which is the maximum normally prescribed, and twice the amount which is allowed over the counter - doubled the risk of heart failure, from 3 to 7 cases in 1,000, and more than doubled the risks of complications such as bleeding ulcers, the study found.
However, the findings, from an analysis of 639 randomised trials, found that a third drug, called naproxen, did not increase the risk of heart attacks or strokes, when a high dose of 1000 mg a day was taken.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
